pancreatic cancer
Conditions
Interventions
Concurrent radiotherapy with S-1: S-1 (80mg/m2) on the irradiated day, Radiotherapy
a total dose of 50.4 Gy in 28 fractions. Systemic Gemcitabine therapy: Gemcitabine (1000mg/m2) is given by intravenous infusion over 30 min on days 1, 8, 15 every 4 week. This cycle was repeated 3 cy
Sponsors
Hokkaido Pancreatic Cancer Study Group (HOPS)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pathologically or cytologically proven diagnosis of pancreas cancer. 2) Definition of a Borderline resectable pancreatic cancer is filled in NCCN guidelines 2012 pancreatic adenocarcinoma 3) No hepatic metastasis by EOB-MR 4) Patients of age =>20 and 75> 5) Performance Status:0-1 (ECOG) 6) Adequate oral intake 7) Good main organ function 8) Written informed consent
Exclusion criteria
Exclusion criteria: 1) treatment history of a pancreatic cancer (chemotherapy, radiotherapy, surgical) 2) treatment history of other malignant tumors (chemotherapy, radiotherapy) 3) Patients who can' t receive neither iodic drug because of drug allergy 4) Including in an exposure field is impossible with contrast enhanced CT 5) Massive pleural or abdominal effusion 6) Pleural membranes and peritoneum sowing are proved by cytological diagnosis 7) Existence of tumor exposure with CT or Endoscope 8) Hemorrhagic peptic ulcer 9) Watery diarrhea 10) Regular use of frucitocin, fenitoin or warfarin 11) Lung fibrosis or intestinal pneumonia, and anamnesis or imaging findings 12) Severe infection 13) Serious complications (e.g. heart failure, hepatic failure, intestinal paralysis, intestinal obstruction) 14) Uncontrolled diabetes 15) Simultaneous or metachronous (within 3 years) double cancers 16) Patients requiring systemic steroids medication 17) Severe mental illness 18) Severe drug hypersensitivity 19) Males that are currently attempting to produce a pregnancy 20) Pregnant females, possibly pregnant females, females wishing to become pregnant 21) Patients seems inadequate for this study by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R0 resection rate | — |
Secondary
| Measure | Time frame |
|---|---|
| completion rate, pathological effect , Response rate, CA19-9 response rate, progression free survival, distant metastasis free survival, overall survival, adverse effect, surgical complication | — |
Countries
Japan
Contacts
Public ContactTsuyoshi Hayashi
Sapporo Medical University Department of Medical Oncology and Hematology
Outcome results
None listed